At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Multicenter, Phase 2 Study of a Human Monoclonal Antibody to Human av Integrins (CNTO 95) in Combination With Docetaxel for the First-Line Treatment of Subjects With Metastatic Hormone Refractory Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating Docetaxel, Prednisone, and 2 other interventions for Prostatic Neoplasms. Completed, enrolled 131 participants across 59 sites in 10 countries.
Detailed Summary
The purpose of this study is to assess the effects of intetumumab when given in combination with docetaxel and prednisone to participants with metastatic (spread of cancer cells from one part of the body to another) hormone-refractory (not responding to treatment) prostate cancer (abnormal tissue that grows and spreads in the body until it kills).
Study Details
Timeline
Interventions
Docetaxel 75 mg/m\^2 as intravenous infusion every 3 weeks.
Prednisone 5 mg orally twice daily.
Intetumumab 10 mg/kg as intravenous infusion every week for initial 6 weeks, then every 3 weeks.
Placebo matching to intetumumab, as intravenous infusion every week for initial 6 weeks, then every 3 weeks.